Quality of life at 6 months in the Idiopathic Intracranial Hypertension Treatment Trial

Conclusions:
The marked reductions in baseline QOL seen among patients with mild visual loss from IIH are improved by treatment with acetazolamide. When combined with acetazolamide-associated improvements in visual field and other aspects of IIH, our findings with respect to QOL provide further support from the IIHTT in favor of acetazolamide to augment a dietary intervention in the treatment of IIH with mild visual loss (clinicaltrials.gov: NCT01003639).

Source: Neurology - October 30, 2016 Category: Neurology Authors: Bruce, B. B., Digre, K. B., McDermott, M. P., Schron, E. B., Wall, M., On behalf of the NORDIC Idiopathic Intracranial Hypertension Study Group Tags: Idiopathic intracranial hypertension, Quality of life ARTICLE Source Type: research